Iconovo

ICO · Nasdaq Stockholm · Healthcare

1.25SEK −1.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: −42.1%

Performance

1 month

−5.7%

1 year

−42.1%

3 years, per year

−53.4%

5 years, per year

−56.6%

Largest fall, 3 years

−98.5%

Below the peak now

−98.7%

Volatility, 1 year

49.6%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.8

Dividend yield

0.0%

Return on equity

−26.3%

Net margin

−193.1%

Market value

12 m USD

Quality, value and trend

Where Iconovo stands against every Nordic stock today. 100 is best.

Quality82

Profitability and a sound balance sheet over time. Better than 82% of Nordic stocks.

Value23

The price measured against earnings, assets and cash flow. Better than 23% of Nordic stocks.

Trend53

The price development over the past year. Better than 53% of Nordic stocks.

Combined50

Quality, value and trend together. Better than 50% of Nordic stocks.

About Iconovo

Iconovo is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 12 employees.

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis